Metagenomi Therapeutics (MGX) Net Cash Flow (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Net Cash Flow of -$17.2 million for Q1 2026, down 1051.69% year-over-year from $1.8 million in Q1 2025, and down 293.57% quarter-over-quarter from $8.9 million in Q4 2025.
Metagenomi Therapeutics (MGX) Net Cash Flow (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Net Cash Flow for 4 consecutive years, with -$17.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 1051.69% year-over-year to -$17.2 million; the TTM figure through Mar 2026 stood at -$4.7 million (up 93.53% YoY), while the FY2025 annual figure was $14.3 million, up 112.61% from the prior year.
- Net Cash Flow eased to -$17.2 million in Q1 2026 per MGX's latest filing, from $8.9 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $50.2 million in Q3 2023 and bottomed at -$88.8 million in Q1 2023.
- Historically, Net Cash Flow has averaged -$12.4 million across 4 years, with a median of -$2.3 million in 2025.
- Annual changes were most pronounced in 2025 — Net Cash Flow surged 291.98% — and 2026, when it tumbled 1051.69%.
- Metagenomi Therapeutics' Net Cash Flow stood at $38.7 million in 2023, then tumbled by 94.14% to $2.3 million in 2024, then soared by 291.98% to $8.9 million in 2025, then tumbled by 293.57% to -$17.2 million in 2026.
- Business Quant data shows MGX's Net Cash Flow at -$17.2 million in Q1 2026, $8.9 million in Q4 2025, and $5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | 13.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.72 Mn |
| Jun 30, 2026 | 13.72 Mn |
| Mar 31, 2026 | -17.22 Mn |
| Mar 31, 2026 | -17.22 Mn |
| Dec 31, 2025 | 8.89 Mn |
| Dec 31, 2025 | 8.89 Mn |
| Sep 30, 2025 | 5.92 Mn |
| Sep 30, 2025 | 5.92 Mn |
| Jun 30, 2025 | -2.35 Mn |
| Jun 30, 2025 | -2.35 Mn |
| Mar 31, 2025 | 1.81 Mn |
| Mar 31, 2025 | 1.81 Mn |
| Dec 31, 2024 | 2.27 Mn |
| Dec 31, 2024 | 2.27 Mn |
| Sep 30, 2024 | -36.06 Mn |
| Sep 30, 2024 | -36.06 Mn |
| Jun 30, 2024 | -41.38 Mn |
| Jun 30, 2024 | -41.38 Mn |
| Mar 31, 2024 | -38.05 Mn |
| Mar 31, 2024 | -38.05 Mn |